Opinion
Video
NCCN Guidelines 2023: Updates in Myelofibrosis Management
Aaron Gerds, MD, MS, discusses key updates in the National Comprehensive Cancer Network (NCCN) guidelines for myelofibrosis, including new treatments such as momelotinib and refined recommendations for different patient populations. He reviews symptom management, spleen size, and supportive care measures for optimal patient outcomes.
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Gerds discusses the 2023 updates in the NCCN guidelines for myelofibrosis (MF), highlighting the approval of momelotinib, the fourth JAK inhibitor. The guidelines underwent refinements, particularly in the realm of polycythemia vera and myelofibrosis. Gerds emphasizes the challenge of positioning 4 JAK inhibitors strategically, considering patient populations and sequencing. For symptomatic low-risk MF patients, the focus is on symptom and spleen size management. Ruxolitinib remains a first-line choice, but momelotinib addresses anemia, and pacritinib is considered for thrombocytopenia. Gerds delves into supportive care measures for maximizing patients' quality of life, specifically addressing anemia, which is prevalent in MF. The guidelines provide a detailed approach, distinguishing therapeutics targeting anemia alone or addressing multiple aspects like spleen and symptoms. Gerds encourages assessing patient symptoms and functional thresholds to determine intervention timing. Recognizing blood bank shortages, he emphasizes responsible resource use. The discussion provides valuable insights into the evolving NCCN guidelines and personalized approaches to MF treatment.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
